Emyria (FRA:Q84) Defensive Interval Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Emyria Defensive Interval Ratio?

Emyria Business Description

Other Exchanges EMD:Australia
Address D2, 661 Newcastle Street, PO Box 1442, Leederville, WA, AUS, 6007
Emyria Ltd is an Australian healthcare and drug development company focused on psychedelic-assisted therapies and cannabinoid-based medicines. It operates specialist medical clinics that provide mental health and pain management services, generating clinical data from consenting patients through its proprietary software platform. This data supports its drug development programs, which include MDMA-assisted therapy for post-traumatic stress disorder and other psychedelic compounds. The company also conducts clinical trials and research collaborations with academic institutions. Emyria's revenue comes from patient consultations and treatments at its clinics, as well as from research partnerships and licensing arrangements. Its operations are primarily based in Australia, with a focus on developing and commercializing novel therapies for unmet mental health needs.